The primary therapeutic domain of Caverject DC is the symptomatic management of Erectile Dysfunction (ED), a condition where symptoms related to physical discomfort and functional strain interfere with daily functioning. The medication is commonly used across conditions presenting with chronic or recurrent symptomatic failure. It is applied in situations involving distressing symptoms that may become disruptive, such as those linked to organ-specific functional stress or other factors.

The medication is utilized for the symptomatic management of ED, focusing on patients who experience a persistent or recurrent failure to achieve or sustain sufficient penile firmness. It is applied across therapeutic domains where additional symptomatic support is needed, and is considered relevant in situations where patients experience symptomatic patterns that require intensive support. It is also often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed. This provides support that helps ease the overall symptom burden and may assist with coping more steadily with symptom fluctuations.

“provides support that helps ease the overall symptom burden, and may assist with coping more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Erectile Deficit

Property	Description
Primary Indication	Symptomatic management of Erectile Dysfunction (ED)
Symptom Focus	Persistent failure to achieve/maintain penile rigidity
Typical Context	Relevant when supportive symptom management is appropriate
Main Benefit	Supports functional stability and helps ease symptom burden

Who Can and Cannot Use Caverject DC?

Eligibility to use Caverject DC is strictly defined by regulatory documents, focusing on patient status and specific medical conditions. The medication is officially indicated exclusively for adult men (generally age 18 and older).

Who Must Not Use This Medicine (Contraindications)

Official labeling identifies several populations for whom use is absolutely contraindicated (prohibited):

• Predisposition to Priapism: Men with blood disorders that increase the risk of a prolonged erection, including sickle cell anemia (or trait), multiple myeloma, or leukemia.
• Anatomical Restrictions: Men who have a penile implant or those with anatomical deformations of the penis, such as Peyronie’s disease, cavernosal fibrosis, or severe angulation.
• Medical Fitness: Men for whom sexual activity is medically inadvisable due to underlying non-ED conditions (e.g., severe cardiovascular disease).

Conditional Eligibility and Age Restrictions

Population Group	Eligibility Status	Basis for Restriction
Children/Adolescents	Not Indicated	Safety and effectiveness are not established in this age group.
Older Adults (≥ 65)	Eligible	No specific dose adjustments are required solely based on age.
Bleeding Disorders/Anticoagulants	Conditional Use	Caution is required due to increased risk of injection site bleeding or hematoma.

Eligibility criteria are governed by official governmental prescribing information, which focuses on excluding high-risk populations.

Interactions with other medicines and products

The official regulatory profile for Caverject DC (Alprostadil) is primarily focused on pharmacodynamic interactions due to its localized route of administration and low systemic exposure.

Documented Pharmacodynamic Interactions

Interacting Class/Substance	Official Regulatory Outcome	Constraint/Restriction
Other Vasoactive Agents injected intracavernosally	Increased risk of prolonged erection, priapism, and hypotension may occur.	Co-administration is not recommended; safety and efficacy are not established.
Anticoagulants and Platelet Aggregation Inhibitors (e.g., Warfarin, Heparin)	Enhanced effects leading to an increased propensity for injection site bleeding or hematoma.	Procedural guidance requires compression of the injection site for a specified duration.
Antihypertensives and other Vasodilative Agents	Potential for enhanced effects, possibly leading to additive hypotension.	Alprostadil may potentiate the effect of these agents.
Sympathomimetics	May reduce the therapeutic effect of Alprostadil.	Effect counteraction is officially documented.

Pharmacokinetic and Metabolic Profile

The potential for pharmacokinetic drug-drug interactions (such as those mediated by CYP enzymes or transporters) between Alprostadil and other agents has not been formally studied according to regulatory documents. Consequently, no officially documented interactions with food, alcohol, or herbal products are established in the official prescribing information.

Caverject DC Mechanism of Action

Alprostadil, the active ingredient, is a synthetic analog of prostaglandin E1 (PGE1). Following intracavernosal administration, it acts locally within the corpus cavernosum of the penis. Alprostadil binds to and activates specific PGE1 receptors, primarily EP2 and EP4 subtypes, located on the smooth muscle cells lining the cavernosal arteries and trabeculae.

Activation of these receptors stimulates the adenylyl cyclase enzyme. This action leads to an increase in the intracellular concentration of cyclic adenosine monophosphate (cAMP). The elevated cAMP initiates an intracellular cascade: it activates protein kinase A (PKA), which then phosphorylates target proteins, including L-type calcium channels and myosin light-chain kinase (MLCK).

The resulting decrease in intracellular calcium (Ca^2+) concentration causes the relaxation of the smooth muscle cells. This relaxation allows the penile arteries and the sinusoidal spaces within the corpus cavernosum to dilate, increasing blood flow into the penile tissue. The action is localized and terminated rapidly by the metabolism of Alprostadil via 15-hydroxyprostaglandin dehydrogenase.

How Caverject DC is Used: Official Administration and Dosing

The administration of Caverject DC is precisely defined, requiring controlled use via its designated route. The medication is delivered as a lyophilized powder for injection in a dual-chamber system, which must be reconstituted immediately prior to use with the provided sterile diluent.

Approved Administration Route

Category	Details
Route of Administration	Intracavernosal injection (direct administration into the corpus cavernosum of the penis).
Dosing Constraint	Use is constrained to the lowest effective dose that produces an erection suitable for intercourse, lasting no longer than one hour.

Standard Labeled Dosing Regimen

The required dose is determined through a supervised, mandatory dose titration process conducted entirely within the healthcare provider's office. This ensures the patient is trained and the lowest effective dose is identified.

Indication (Etiology)	Starting Dose (In-Office)	Maximum Frequency
Vasculogenic, Psychogenic, or Mixed ED	2.5 mcg	No more than 3 times weekly
Pure Neurogenic ED	1.25 mcg	Minimum 24 hours between doses

During titration, the dose may be increased incrementally, but the maximum recommended dose per injection is generally 60 mcg. The patient must alternate the injection site (right or left side) with each use and administer the solution along the dorso-lateral aspect of the proximal third of the penis. No specific dose adjustments are provided in the standard labeling for older adults or patients with renal or hepatic impairment.

Research evidence / Overview of Studies for Caverject DC

The core research evidence for this medication was studied for the symptomatic management of Erectile Dysfunction (ED), a condition characterized by functional limitations. Researchers have primarily relied on Randomized Controlled Trials (RCTs) to evaluate how research explored specific physical and functional outcomes related to the agent's administration. These trials were designed to be double-blind and placebo-controlled, meaning neither the participants nor the research staff knew who was receiving the active agent versus an inactive substance. This design is relevant in trials assessing short-term or episodic symptom patterns and studies contribute to the broader evidence landscape.

Study Designs and Measured Outcomes

The studies monitored outcomes related to physiological strain or stress and daily functioning. Research examined the patient-reported outcomes describing perceived discomfort and whether an erection sufficient for sexual intercourse was reported, an outcome reflecting daily functioning or activity level. Beyond patient self-reports, researchers used specific objective measures to monitor physiological strain or stress in the observed populations. For instance, objective rigidity assessments using devices like RigiScan were conducted to track the hardness and duration of the physical response.

---

Long-Term Studies and Follow-Up Data

Research has explored outcomes beyond the initial treatment phase of the key controlled trials. The follow-up durations for the primary efficacy assessments in the RCTs were typically short-term, often spanning only a few weeks. For longer-term observations, researchers conducted open-label extension studies. This open-label format research explored use in observational settings evaluating daily-life functioning. However, because these follow-up studies were not placebo-controlled or blinded, the evidence quality varies across studies, and long-term effects are not fully established.

---

What is Still Uncertain About the Research for Caverject DC

The evidence, while structured around controlled trials, has some important limitations. The follow-up durations were limited in the most rigorously controlled studies, meaning long-term outcomes are not well characterized. Furthermore, studies observing patient self-administration over intermediate-term follow-up were associated with relatively high reported dropout rates. The research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Research provides context but not individual predictions.

Common questions about Caverject DC (FAQ)

---

Q: How long does it take for Caverject DC to start working after injection?

Official information indicates that an erection may occur within 5 to 20 minutes after administration. The dose is intended to produce an erection suitable for intercourse and lasting no longer than one hour.

---

Q: What should I do if my erection lasts longer than 4 hours?

If an erection persists for longer than 4 hours, official labeling advises patients to immediately report to a physician or seek emergency medical assistance. An erection lasting six hours or more is classified as Priapism, which is a serious condition that requires prompt treatment.

---

Q: Does this medication need to be refrigerated after mixing?

No, the official product information specifies that the reconstituted solution should not be refrigerated or frozen. The solution is for single use only, and after mixing, it should be kept at or below 25 C (77 F) and used within 24 hours.

---

Q: What are the steps for mixing the Caverject DC powder and diluent?

The mixing process is a key part of the required patient training provided by a healthcare professional prior to home use. The general preparation involves combining the powder and liquid within the dual-chamber system and gently mixing the solution to ensure the medicine fully dissolves before it is administered.

---

Q: Is it safe to use Caverject DC if I have high blood pressure?

Official information notes that caution is advised for the use of this medicine in populations with cardiovascular or cerebrovascular risk factors or unstable heart conditions. Additionally, the medicine is contraindicated (prohibited) for men whose underlying medical status, such as severe cardiovascular disease, makes sexual activity medically inadvisable.

---

Q: Can the injection be painful, and is there a way to reduce the pain?

Studies and official safety profiles classify penile pain as the most frequently reported adverse reaction, noted as a 'very common' effect. While official product information documents this pain, the prescribing information does not contain specific instructions or recommendations for pain reduction measures.

How to Store and Dispose of Caverject DC

Official regulatory labeling dictates strict conditions for the storage and disposal of Caverject DC (alprostadil).

---

Storage Requirements

The unreconstituted powder must be stored at Controlled Room Temperature (20 C to 25 C), protected from light and moisture in its original container. The product must not be frozen. Once mixed, the reconstituted solution is for single use only and must be used within 24 hours, maintaining a temperature between 2 C and 25 C during this period. The medicine must be kept out of the sight and reach of children.

---

Disposal Instructions

Used needles, syringes, and all injection components must be placed immediately into an FDA-cleared sharps disposal container. Needles and syringes must not be thrown away in household trash or flushed down the toilet. Any unused product or waste material must be disposed of according to local requirements.